BIIB - Biogen Inc.
237.83 -0.24 (-0.10%)
After hours: 7:33PM EDT
| Previous Close | 240.29 |
| Open | 241.45 |
| Bid | 238.26 x 1000 |
| Ask | 237.84 x 1000 |
| Day's Range | 235.92 - 242.68 |
| 52 Week Range | 216.12 - 388.67 |
| Volume | 1,412,362 |
| Avg. Volume | 2,159,946 |
| Market Cap | 46.16B |
| Beta (3Y Monthly) | 1.62 |
| PE Ratio (TTM) | 10.29 |
| EPS (TTM) | 23.14 |
| Earnings Date | Jul 23, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 253.63 |
- TheStreet.com•12 hours ago
Biogen Could Rally in the Weeks Ahead
In this daily bar chart of BIIB, below, we can see a three-month sideways pattern after the huge downside price gaps in March. Trading volume has been higher since late March than it was in previous months. The daily On-Balance-Volume (OBV) line chopped sideways in April and May but it has strengthened this month and suggests that buyers of BIIB have become more aggressive.
- TheStreet.com•13 hours ago
AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
- Motley Fool•2 days ago
The 10 Biggest Biotech Stocks
Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.
- Zacks•2 days ago
5 ROE Stocks to Buy as Trade Talks Resume Ahead of G20 Summit
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
- Zacks•2 days ago
3 Reasons Why Growth Investors Shouldn't Overlook Biogen (BIIB)
Biogen (BIIB) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- Zacks•2 days ago
The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon
The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon
- Zacks•3 days ago
Top Stock Reports for Union Pacific, NextEra & Biogen
Top Stock Reports for Union Pacific, NextEra & Biogen
- American City Business Journals•7 days ago
Biotech companies dominate fastest-growing public companies list again
Biotech companies once again dominate the BBJ’s annual list of fastest-growing public companies in Massachusetts. Paratek Pharmaceuticals Inc., headquartered in Boston, ranks first on the list this year with revenue growth between 2016 and 2018 of 58,924 percent.
- InvestorPlace•8 days ago
3 Large-Cap Biotech Stocks to Buy for Massive Gains
Do you want to find the next Apple (NASDAQ:AAPL) or Amazon (NASDAQ:AMZN)? My advice is that you should set your sights lower, not higher and put some cash to work in three down, but not out heavyweight biotech stocks for the next big thing in investing. Let me explain.It has been a good week so far for the broader markets. The Nasdaq Composite, S&P 500 and Dow Jones Industrial Average have broken out of short bases barely discernible on the weekly chart and back within spitting distance of their respective all-time-highs following May's abrupt correction. It has been a nice period for biotech stocks as well.The Vaneck Vectors Biotech ETF (NYSEARCA:BBH) is up nearly 3.50% through Tuesday's close compared to gains of roughly 1% to 2% for the broader averages. But as any investor with a passing interest in the markets knows, the outperformance in biotech stocks has been anything but a recurring theme these past couple years.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer The good news is markets are cyclical. Even legendary investments such as AMZN or the sacrosanct AAPL stock have been known to correct for periods lasting not weeks, but months and even years. With that in mind, it's time to consider adding these three large-cap biotech stocks into your portfolio. Amgen (AMGN) Click to EnlargeAmgen (NASDAQ:AMGN) is a biotech heavyweight that also happens to be the sector's largest capitalization outfit with a valuation of about $110 billion.Following a recent sales and earnings beat, this reasonably-priced biotech giant, which pays investors nearly 3.5% in quarterly dividends, has now put together a bottom on the monthly price chart.Specifically, AMGN stock has formed a confirmed pivot low, which reaffirms its longstanding uptrend after a correction of several months. And with plenty of lateral, angular and Fibonacci price supports, as well as an oversold crossover signal to confirm the bottom, this biotech stock is a buy today.The TradeBuy AMGN stock at current prices. Set a stop-loss beneath support below $160, but expect shares to hit new highs in 2019's second half. Gilead Sciences (GILD) Click to EnlargeIt has been a rough few years for Gilead Sciences (NASDAQ:GILD), one the sector's largest names, but things are looking up for GILD stock lately.A recent earnings report that reiterated the company's full-year guidance and offered a modest year-over-year uptick in sales and profits looks promising for Gilead shares, which have been absolutely pummeled over the last four years.Technically, shares are trading slightly above multiple inside candlesticks following a double bottom pattern of about one and a half years. With the formation finding support off the 50% retracement level and a supportive-looking stochastics set-up signaling better months and years ahead, GILD stock looks good to buy right now. * 10 'Buy-and-Hold' Stocks to Own Forever The TradeBuy GILD stock at current levels with an initial stop-loss below $59. On the upside, $85 - $90 looks like a good area for profit-taking while allowing this down-and-out value stock some room to run. Biogen (BIIB) Click to EnlargeMuch like GILD stock, shares of sector heavyweight Biogen (NASDAQ:BIIB) have been under extreme technical duress the past few years.Most recently, the pain in BIIB stock came after the company's announcement that it was axing a drug to treat Alzheimer's following poor results. The suffering came despite the fact that BIIB posted stronger-than-forecast results in late April.On the price chart, this biotech stock's technical beating since 2015 has resulted in a possible four-year long double-bottom pattern that's finding support in-between the 50% and 62% retracement levels. Coupled with an oversold stochastics that is a hair's breadth away from signaling a bullish crossover, confirmation of the pivot low looks imminent.The TradeBuy BIIB stock above May's candle high of $238.17 to confirm the pattern bottom. I'd suggest an initial stop beneath $214 and to take partial profits in-between $300 - $310.Disclosure: Investment accounts under Christopher Tyler's management currently do not own positions in any of the securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post 3 Large-Cap Biotech Stocks to Buy for Massive Gains appeared first on InvestorPlace.
- Markit•9 days ago
See what the IHS Markit Score report has to say about Biogen Inc.
Biogen Inc NASDAQ/NGS:BIIBView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BIIB had net inflows of $1.76 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•9 days ago
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
Pfizer could be only the first of several to spend billions buying smaller biotech.
- MarketWatch•9 days ago
Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
- Zacks•10 days ago
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
- Investor's Business Daily•13 days ago
Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
- Zacks•14 days ago
Biogen (BIIB) Gains But Lags Market: What You Should Know
Biogen (BIIB) closed the most recent trading day at $230.86, moving +0.19% from the previous trading session.
- MarketWatch•14 days ago
Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s
Amgen Inc., Biogen Inc., Gilead Inc. and Novo Nordisk A/S all have “very high” capacity for M&A activity, Moody’s Investors Service said in a report published Thursday.
- Simply Wall St.•15 days ago
Biogen Inc. (NASDAQ:BIIB) Insiders Increased Their Holdings
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
- Zacks•15 days ago
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
- GlobeNewswire•16 days ago
Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019
Data to be presented at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high.
- InvestorPlace•16 days ago
Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder
Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) are surging Tuesday after the company landed a patent for the treatment of autism spectrum disorder. Specifically, the patent covers treatment using cannabidiol, which will surely add a spark to ZYNE stock.Source: Zynerba PharmaceuticalsThe stock was up 8% in pre-market trading and there's potential for this name to run even further once investors catch wind of it. We're seeing that play out now, with shares up 18% in Tuesday morning trading.With a market capitalization just under $250 million, it's not a well-known player like Biogen (NASDAQ:BIIB) or Celgene (NASDAQ:CELG). In the same light, it's not even a well-known cannabis stock, like Canopy Growth (NYSE:CGC) or Aurora Cannabis (NYSE:ACB).InvestorPlace - Stock Market News, Stock Advice & Trading TipsZynerba was issued U.S. Patent No. 10,314,792, which is titled, "Treatment of Autism Spectrum Disorder with Cannabidiol" and runs through 2038. So if the treatment is successful, ZYNE stock will have the rights to this treatment for almost two decades. The PatentZynerba is building out a portfolio of different treatments based around its potential cannabidiol product Zygel. I say "potential" because there's still a lot of work and progress needed before this becomes a staple in the medicine cabinet, so to say. * 7 Dark Horse Stocks Winning the Race in 2019 The patented treatment "includes claims directed to methods of treating autism spectrum disorder by administering a therapeutically effective amount of synthetic cannabidiol." It was granted during the enrollment period of a Phase 2 BRIGHT study, which is intended to evaluate "the safety, tolerability and efficacy of Zygel for the treatment of children and adolescents with Autism Spectrum Disorder."Will it work? At this stage it's impossible to say, but there is promise. GW Pharmaceuticals (NASDAQ:GWPH) has successfully gained traction -- even here in the U.S. -- with its cannabidiol treatment for epileptic seizures. So if Zynerba can show similar successes with its treatment, it may open the door to other possible treatments in the future using its Zygel product. Trading ZYNE Stock Click to Enlarge The big boost in ZYNE stock comes as little surprise. After all, it's got all the right buzzwords working in its favor, even if the company has good intentions. Wall Street latches to these trends and investors aren't afraid to jump on board if they think there's opportunity. That's even as Phase-2 testing has yet to begin.ZYNE stock chart is one of only a few that could make a double-digit gain look fairly modest. Above you can see how it moved over downtrend resistance (blue line) on Monday. Now it's pushing through $13, as well as the 20-day moving average.Can this thing ignite through $14 and tag its 2019 high near $16.50? Yes, it can. There's no guarantee that it will, but these sort of momentum boosters can give a huge shot in the arm to small-cap stocks.Whether that justifies a move this powerful, ZYNE stock investors certainly have a reason to be excited. But there's a lot of room on the upside before Zynerba stock exhausts itself.On the downside, I want to see $11 to $11.50 hold as support.This marks the 50-day moving average (which is trending higher) as well as the 38.2% retracement. That said, it would be highly discouraging to see ZYNE stock lose all of Tuesday's gains. Bottom Line on ZYNE StockNorth of $13 and the 20-day would be best, but let's see how it trades throughout the day and the rest of this week.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long CELG. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Dark Horse Stocks Winning the Race in 2019 * 6 Chinese Stocks to Sell That Are Suffering From a Digital Ad Slowdown * 4 Technology Stocks Blasting Higher Compare Brokers The post Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder appeared first on InvestorPlace.
- Insider Monkey•17 days ago
Is Biogen Inc. (BIIB) A Good Stock To Buy?
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
- Zacks•20 days ago
Biogen (BIIB) Outpaces Stock Market Gains: What You Should Know
Biogen (BIIB) closed the most recent trading day at $227.33, moving +1.33% from the previous trading session.
- Zacks•20 days ago
Celgene's Filing for Ozanimod Accepted for Review in US/EU
The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.
- GlobeNewswire•20 days ago
Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology.
